Scancell Holdings Secures £2.7 Million in Oversubscribed Retail Fundraising Ahead of AIM Listing

Scancell’s Immuno-Oncology Focus and Market Position

Scancell Holdings plc operates as a late-stage clinical immuno-oncology company, developing therapies that activate the immune system to fight cancer. The company’s strategy emphasizes active immunotherapies designed to boost anti-tumour immune responses, particularly against cancers resistant to conventional treatments. This places Scancell in a competitive yet vital oncology segment where innovative immunological approaches attract significant clinical and investor interest.

The immuno-oncology sector has experienced sustained growth over the last decade, driven by successes such as checkpoint inhibitors and other immune-modulating therapies. Scancell’s focus on active immunotherapies, rather than passive checkpoint modulators, differentiates its approach. Its late-stage clinical status indicates progression through advanced human trials, a milestone that typically garners market and investor confidence. The oversubscribed fundraising reflects positive investor sentiment toward Scancell’s pipeline and development trajectory within the broader immuno-oncology landscape.

Details of the Oversubscribed Retail Fundraise

On 27 July 2026, Scancell announced its retail offer was significantly oversubscribed, raising £2.7 million in gross proceeds versus an initial £2.3 million target. Shares were priced at 9 pence each, with 30,004,836 new ordinary shares to be issued under the retail offer. The board increased the offer size to strengthen the company’s balance sheet amid strong investor demand.

The retail offer was facilitated via the Winterflood Retail Access Platform (WRAP), enabling retail investors to participate alongside institutional investors. Due to high demand, allocations were scaled back with preference given to existing shareholders, a common practice to reward loyal investors. This retail component broadens Scancell’s shareholder base and may enhance stock liquidity post-admission.

Combined Institutional and Retail Capital Raise Totals £15.7 Million

The retail offer complements a concurrent UK institutional placing, with combined gross proceeds of approximately £15.7 million (around $21.0 million). This includes 144,444,444 shares from the institutional placing and 30,004,836 shares from the retail offer. This substantial capital injection supports the company’s clinical development at a critical stage.

The size of the raise aligns with typical funding needs for late-stage clinical immuno-oncology programs, which require ongoing investment in trials, manufacturing, regulatory processes, and operations. The successful execution of both institutional and retail components, including the retail oversubscription, indicates strong investor confidence in Scancell’s strategy and clinical progress. Completing the raise ahead of AIM admission removes near-term financing uncertainties and provides resources to advance the pipeline and working capital.

AIM Admission and Expanded Share Capital Structure

Scancell has applied to London Stock Exchange plc for admission of both placing and retail shares to trading on AIM. Admission is expected to become effective and trading to commence at 8:00 a.m. on or around 28 July 2026. Admission is conditional on the effectiveness of the listing, a standard safeguard ensuring capital deployment within a regulated public market.

Post-admission, the company will have 1,212,230,683 ordinary shares outstanding, each with one voting right, with no shares held in treasury. This share count is critical for regulatory disclosures under the FCA’s Disclosure Guidance and Transparency Rules, informing shareholders and market participants of thresholds for mandatory notifications and concert party obligations.

Rights and Ranking of New Ordinary Shares

New ordinary shares issued via the retail offer will be free from liens, charges, or encumbrances and will rank pari passu in all respects with shares issued in the institutional placing and existing ordinary shares. This equal ranking ensures all shareholders have identical economic, voting, and governance rights, simplifying share register management and aligning with best practice governance for AIM-listed companies.

This parity guarantees that existing shareholders’ voting power and economic interests are diluted only proportionally to the increase in total shares outstanding, maintaining fairness across all share classes.

Oversubscription and Investor Demand Strength

The retail offer’s significant oversubscription reflects strong market confidence in Scancell’s prospects. Initially targeting £2.3 million, the offer was increased by approximately 17% to £2.7 million due to robust demand. Despite this increase, allocations were scaled back to manage excess applications, a common outcome in popular offers.

High retail investor interest may broaden the shareholder base and improve liquidity post-admission. Retail investors often represent long-term, committed participants who perceive value in Scancell’s immuno-oncology platform. The board’s decision to upsize the offer underscores management’s confidence in capital deployment and strategic direction, reinforcing positive market perceptions.

Regulatory and Governance Framework

This fundraising constitutes inside information under Article 7 of the Market Abuse Regulation (EU) 596/2014, incorporated into UK law via the European Union (Withdrawal) Act 2018. Publication of this announcement satisfies transparency requirements. Alex Hayward, Finance Director and Company Secretary, is responsible for the announcement’s release, ensuring proper corporate governance oversight.

Panmure Liberum Limited acted as nominated adviser, placement agent, and joint broker for the institutional placing. Panmure Liberum is FCA-authorised and regulated in the UK, ensuring compliance with AIM Rules. The retail offer was managed through Winterflood Retail Access Platform by Winterflood Securities, also FCA-authorised and regulated. This multi-party regulatory framework provides investor protections and transparency consistent with UK listing standards.

Forward-Looking Outlook and Pipeline Advancement

The £15.7 million gross proceeds provide Scancell with the financial runway to advance its late-stage clinical immuno-oncology programs. Although specific clinical timelines or regulatory milestones were not disclosed, the fundraising scale and oversubscription indicate investor confidence in progressing toward potential commercialisation. Late-stage development typically involves capital-intensive Phase II and III trials, representing key value inflection points if successful.

Investors will likely watch for updates on clinical trial progress, regulatory interactions with agencies such as the EMA and MHRA, and potential partnerships or licensing deals that could accelerate market access or reduce development risk. The strengthened balance sheet positions Scancell to sustain development without near-term capital raises, assuming clinical programs proceed as planned.

AIM Market Context and Trading Prospects Post-Admission

Listing on AIM, the London Stock Exchange’s market for smaller-cap, growth-oriented biotech firms, situates Scancell within a regulatory environment tailored for emerging companies. AIM offers less stringent governance than the main market but maintains FCA oversight and listing standards. The post-admission share count of 1,212,230,683 ordinary shares will serve as the basis for future disclosure and concert party calculations.

Trading is expected to commence on 28 July 2026, transitioning Scancell from private fundraising to public market participation. Shares will become freely tradable subject to any lock-in arrangements. Initial share price impact was not disclosed. Future liquidity will depend on shareholder base diversity, broker coverage quality, and frequency of clinical updates. Admission provides investors from the institutional and retail offers with a liquid exit and transparent price discovery via AIM, eliminating the illiquidity premium of private holdings.